BILACO Trial: Biliary Atresia - a Severe Complex Congenital Liver Disease
Launched by RIGSHOSPITALET, DENMARK · May 30, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The BILACO Trial is studying biliary atresia, a serious liver condition that affects young children. This disease can lead to severe health issues, including liver failure and problems with brain development. The goal of the trial is to identify risk factors that may cause cognitive impairment (challenges with thinking and learning) in children with biliary atresia. By understanding these factors, researchers hope to determine the best time for liver transplantation to help improve the children's overall health and development.
Children between the ages of 0 and 18 who have biliary atresia or those with a related condition called Tetralogy of Fallot may be eligible to participate. The study will involve a series of tests to evaluate liver function, nutrition, immune system health, and brain development at several points in time. Participants will also have neuroimaging (scans of the brain) and cognitive assessments to monitor their progress. This research aims to gather valuable information that could lead to better treatment plans for affected children and improve their quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Biliary atresia
- • Tetralogy of Fallot
- • Healthy controls
- Exclusion Criteria:
- • - Not able to participate in exams
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Vibeke Brix Christensen, MD, PhD, DMSc
Principal Investigator
Rigshospitalet, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials